Please assess the completion status of the following clinical trial:

Trial Title: Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Disease progression following androgen ablation therapy (hormonal or surgical) by either:~  * Increase in the product of bidimensional diameters of 1 or more radiographically documented sites of measurable disease OR~ * Two consecutive increases in PSA documented over a previous reference value~    * First increase in PSA should occur a minimum of 1 week from the reference value and be confirmed~   * First PSA value is less than the previous value, then patient is eligible provided next PSA is greater than the second PSA~* Testosterone levels documented in the castrate range (i.e., less than 30 ng/mL)~PATIENT CHARACTERISTICS:~Age:~* 18 to 85~Performance status:~* CALGB 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin normal~* SGOT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase normal OR~* Alkaline phosphatase no greater than 4 times ULN if SGOT normal OR~* SGOT no greater than 1.5 times ULN and alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No myocardial infarction within past year~* No significant change in anginal pattern within past 6 months~* No New York Heart Association class II-IV heart disease~* No deep venous thrombosis within past year~Other:~* No significant peripheral neuropathy~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy allowed except taxanes or platinum derivatives~Endocrine therapy:~* See Disease Characteristics~* At least 4 weeks since prior antiandrogens~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).